PIP4K2C — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL379873	0.56	10/20
Jnj-38877605 (SCHEMBL182199)	1.00	2/20
SCHEMBL372070	0.85	2/20
Exelixis (SCHEMBL371899)	0.81	2/20
SCHEMBL371644	0.77	2/20
SCHEMBL371732	0.77	2/20
SCHEMBL509206	0.75	2/20
SCHEMBL371775	0.73	2/20
SCHEMBL372083	0.73	2/20
SCHEMBL371806	0.72	2/20
SCHEMBL371980	0.72	2/20
SCHEMBL372296	0.71	2/20
SCHEMBL372085	0.71	2/20
SCHEMBL469347	0.70	2/20
SCHEMBL469291	0.69	2/20
SCHEMBL372310	0.69	2/20
SCHEMBL371788	0.68	2/20
SCHEMBL469286	0.67	2/20
SCHEMBL371571	0.67	2/20
SCHEMBL469352	0.65	2/20

Clinical trials — most relevant to PIP4K2C by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial	PHASE2/PHASE3	UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	PHASE1	COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome	nan	RECRUITING
Clinical Study Evaluating the Effect of Losartan	nan	RECRUITING
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
PIK3CA in HER2+ BC and pCR Trial	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Study of Proteus Syndrome and Related Congenital Disorders	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PIP4K2C binder may also engage these)

Protein	Name	Similarity
Q91XU3	—	1.000	Q91XU3 →
Q0P5F7	—	0.999	Q0P5F7 →
O88370	—	0.997	O88370 →
Q5R488	—	0.996	Q5R488 →
PIP4K2A	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	0.990	landscape →
PIP4K2B	Phosphatidylinositol 5-phosphate 4-kinase type-2 beta	0.989	landscape →
O88377	—	0.989	O88377 →
Q80XI4	—	0.989	Q80XI4 →
O13010	—	0.985	O13010 →
Q5F356	—	0.979	Q5F356 →
Q9R0I8	—	0.977	Q9R0I8 →
O70172	—	0.977	O70172 →
Q5PQ01	—	0.967	Q5PQ01 →
Q6GL14	—	0.965	Q6GL14 →
Q99NI4	—	0.956	Q99NI4 →
Q6IQE1	—	0.952	Q6IQE1 →
D2XV59	—	0.950	D2XV59 →
Q7TT16	—	0.948	Q7TT16 →
IPMK	Inositol polyphosphate multikinase	0.946	landscape →
Q6PAL8	—	0.946	Q6PAL8 →
IP6K1	Inositol hexakisphosphate kinase 1	0.946	landscape →
Q58DC5	—	0.946	Q58DC5 →
Q9R0U1	—	0.944	Q9R0U1 →
Q9R1D7	—	0.943	Q9R1D7 →
IP6K2	Inositol hexakisphosphate kinase 2	0.943	landscape →
PRKD1	Serine/threonine-protein kinase D1	0.943	landscape →
Q6NYU2	—	0.942	Q6NYU2 →
Q5SWU9	—	0.942	Q5SWU9 →
Q80YV4	—	0.942	Q80YV4 →
Q6DFZ1	—	0.942	Q6DFZ1 →